Jennifer Rui Wang

Jennifer Rui Wang

Auto-generated profile, based on publicly available information

Jennifer Rui Wang

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2020 in Thyroid®
Verified
Journal Article
Closed access
MCMaria E. Cabanillas
Maria E. Cabanillas
RDRamona Dadu
Ramona Dadu
PIPriyanka C Iyer
Priyanka C Iyer
KWKacey Byrne Wanland
Kacey Byrne Wanland
NBNaifa L. Busaidy
Naifa L. Busaidy
MHMarie-Claude Hofmann
Marie-Claude Hofmann
Background: The BRAF V600E mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAF V600E -mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAF V600E -mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually develops. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer to develop future strategies to effectively treat these patients and improve survival. Patients: Herein, we describe four patients with thyroid cancer treated with selective BRAF inhibitors, who developed a RAS mutation in addition to the BRAF V600E mutation at progression. Results: Patients 1 and 3 acquired a KRAS G12V mutation in the progressive tumor, patient 2 acquired a NRAS Q61K mutation in a progressive lymph node, and patient 4 acquired NRAS G13D mutation on liquid biopsy performed at the time of radiographic disease progression. Conclusion: Similar to the melanoma experience, the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.

16 January 2024 in Thyroid®
Verified
Journal Article
Closed access
SHSarah Hamidi
Sarah Hamidi
PIPriyanka C. Iyer
Priyanka C. Iyer
RDRamona Dadu
Ramona Dadu
MGMaria K. Gule-Monroe
Maria K. Gule-Monroe
AMAnastasios Maniakas
Anastasios Maniakas
MCMaria E. Cabanillas
Maria E. Cabanillas
Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAF V600E -mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n =23 in DT and n =48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment ( p =0.427) and prior treatments with surgery ( p =0.864) and radiation ( p =0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p =0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p =0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.

9 November 2020 in Head & Neck
Verified
Journal Article
Open access
PDF file
YJYelda Jozaghi
Yelda Jozaghi
MZMark Zafereo
Mark Zafereo
MWMichelle D. Williams
Michelle D. Williams
MGMaria K. Gule‐Monroe
Maria K. Gule‐Monroe
JWJennifer Wang
Jennifer Wang
MCMaria Cabanillas
Maria Cabanillas
Background: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Administration (FDA)‐approved for advanced MTC. The advent of highly selective, potent RET inhibitors is broadening the treatment options for patients with RET‐mutated cancers.Methods: We report the first published case of neoadjuvant selpercatinib followed by surgery for a patient with initially unresectable, widely metastatic, RET‐mutated MTC who was treated on a single patient protocol.Results: After greater than 50% RECIST response, the patient underwent complete surgical resection followed by selpercatinib resumption. He remains locoregionally disease‐free 21 months after starting therapy with stable metastatic disease (after initial partial response); and calcitonin/CEA continue to decline.Conclusion: This novel treatment strategy for locoregionally advanced RET‐mutated MTC warrants further study in clinical trials.

1 August 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
JWJennifer Rui Wang
Jennifer Rui Wang
MMMatthew Montierth
Matthew Montierth
LXLi Xu
Li Xu
MGMaitrayee Goswami
Maitrayee Goswami
XZXiao Zhao
Xiao Zhao
MCMaria E. Cabanillas
Maria E. Cabanillas
PURPOSE: Anaplastic thyroid carcinoma (ATC) uniformly present with aggressive disease, but the mutational landscape of tumors varies. We aimed to determine whether tumor mutations affect survival outcomes in ATC. MATERIALS AND METHODS: Patients who underwent mutation sequencing using targeted gene panels between 2005 and 2019 at a tertiary referral center were included. Associations between mutation status and survival outcomes were assessed using Cox proportional hazards models. RESULTS: A total of 202 patients were included, where 122 died of ATC (60%). The median follow-up was 31 months (interquartile range, 18-45 months). The most common mutations were in TP53 (59%), BRAF (41%), TERT promoter (37%), and the RAS gene family (22%). Clinicopathologic characteristics and overall survival (OS) significantly correlated with mutations in BRAFV600E and RAS, which were mutually exclusive. The BRAFV600E mutation was associated with the presence of a papillary thyroid carcinoma precursor and significantly better OS (median OS: 24 months). RAS-mutated patients more commonly presented without cervical lymph node involvement but had the worst OS (median OS: 6 months). Tumors that were wild-type for both BRAF and RAS were enriched for NF1 mutations and harbored intermediate prognosis (median OS: 15 months). In multivariate analyses, RAS mutations were associated with a more than 2.5-fold higher risk of death (adjusted hazard ratio, 2.64; 95% CI, 1.66 to 4.20) compared with BRAFV600E. In patients treated with BRAF-directed therapy (n = 60), disease progression occurred in 48% of patients (n = 29). The median progression-free survival was 14 months. The presence of a TP53 mutation was independently associated with reduced progression-free survival in BRAFV600E-mutated patients treated with BRAF-directed therapy (adjusted hazard ratio, 2.89; 95% CI, 1.35 to 6.21). CONCLUSION: Mutation analysis provides prognostic information in ATC and should be incorporated into routine clinical care.

3 August 2021 in Thyroid®
Verified
Journal Article
Closed access
YQYu Qin
Yu Qin
JWJennifer Rui Wang
Jennifer Rui Wang
YWYing Wang
Ying Wang
PIPriyanka C Iyer
Priyanka C Iyer
GCGilbert J. Cote
Gilbert J. Cote
MCMaria E. Cabanillas
Maria E. Cabanillas
Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to facilitate early diagnosis and treatment selection. The relatively rapid turnaround time compared with conventional tumor mutation testing is a major advantage. The objectives of this study were to examine the concordance of ATC-related mutations detected in cfDNA with those detected in the corresponding tumor tissue, and to determine the prognostic significance of cfDNA mutations in ATC patients. Methods: The ATC patients who were diagnosed and treated at The University of Texas MD Anderson Cancer Center between January 2015 and February 2018 and who had cfDNA testing were included in this study. cfDNA was collected by blood draw and was analyzed by next-generation sequencing (NGS) using the Guardant360-73 gene platform. Results: A total of 87 patients were included in the study. The most frequently mutated genes detected in cfDNA were TP53, BRAF , and PIK3CA . In 28 treatment naive ATC patients, the concordance rate of detected mutations in TP53, BRAF V600E , and PIK3CA between cfDNA and matched tissue NGS was 82.1%, 92.9%, and 92.9%, respectively. Patients with a PIK3CA mutation detected on cfDNA had worse overall survival (OS) ( p = 0.03). This association was observed across various treatment modalities, including surgery, cytotoxic chemotherapy, radiation, and BRAF inhibitor (BRAFi) therapy. With regard to treatment, BRAFi therapy significantly improved ATC OS ( p = 0.003). Conclusions: cfDNA is a valuable tool to evaluate a tumor's molecular profile in ATC patients. We identified high concordance rates between the gene mutations identified via cfDNA analysis and those identified from the NGS of the corresponding tumor tissue sequencing. Identified mutations in cfDNA can potentially provide timely information to guide treatment selection and evaluate the prognosis in patients with ATC.

27 April 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AHAnderson Head
Anderson Head
NCNeck Surgery Treatment Guidelines Consortium
Neck Surgery Treatment Guidelines Consortium
AMAnastasios Maniakas
Anastasios Maniakas
YJYelda Jozaghi
Yelda Jozaghi
MZMark E. Zafereo
Mark E. Zafereo
SLStephen Y. Lai
Stephen Y. Lai